B Arrowhead Pharmaceuticals b (ARWR) grabbed an upgrade Friday as ARWR stock has rocketed 159% since October on enthusiasm for the biotech company's RNAi platform. Further, ARWR stock is benefiting from positive results from studies of drugs that treat abnormal lipids and high triglycerides. The biotech company also has a bullish Composite Rating of 98, putting ARWR stock in the top 2% of all stocks in terms of key growth metrics. [Extracted from the article]
Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
